RecruitingPhase 3NCT07037277

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV

An Evaluation of Bemnifosbuvir-Ruzasvir (BEM/RZR) Versus Sofosbuvir-Velpatasvir (SOF/VEL) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in a Phase 3 Randomized, Controlled, Open-label Study

Sponsor

Atea Pharmaceuticals, Inc.

Enrollment

880 participants

Start Date

Jun 2, 2025

Study Type

INTERVENTIONAL

Conditions

Hepatitis C Hepatitis C, Chronic Hepatitis C Virus Infection HEPATITIS C VIRUS CHRONIC INFECTION

Summary

The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.

Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study compares two combination antiviral treatments — BEM/RZR versus sofosbuvir/velpatasvir (SOF/VEL) — for people with chronic hepatitis C virus (HCV) infection. **You may be eligible if...** - You have a documented history of chronic hepatitis C - You have never been treated with direct-acting antiviral drugs for hepatitis C - You have no cirrhosis, or only mild (compensated) cirrhosis - You use adequate contraception if you are able to become pregnant **You may NOT be eligible if...** - You have previously taken any approved or experimental hepatitis C antiviral drug - You have severe (decompensated) cirrhosis - You have serious kidney or liver complications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBemnifosbuvir-Ruzasvir

BEM/RZR Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 8 weeks (in those without cirrhosis) or 12 weeks (in those with compensated cirrhosis)

DRUGSofosbuvir-Velpatasvir

SOF/VEL Fixed-dose Combination (FDC) tablets administered orally once daily for a total of 12 weeks

Locations(106)

Atea Study Site

Nice, Alpes Maritimes, France

Atea Study Site

Strasbourg, Bas Rhin, France

Atea Study Site

Clichy, Hauts De Seine, France

Atea Study Site

Montpellier, Herault, France

Atea Study Site

Clermont-Ferrand, Puy De Dome, France

Atea Study Site

Créteil, Val De Marne, France

Atea Study Site

Frankfurt am Main, Hesse, Germany

Atea Study Site

Leipzig, Saxony, Germany

Atea Study Site

Hamburg, Germany

Atea Study Site

Alexandroupoli, Greece

Atea Study Site

Athens, Greece

Atea Study Site

Athens, Greece

Atea Study Site

Heraklion, Greece

Atea Study Site

Rhodes, Greece

Atea Study Site

Hyderabad, Andhra Pradesh, India

Atea Study Site

Patna, Bihar, India

Atea Study Site

Rajkot, Gujarat, India

Atea Study Site

Surat, Gujarat, India

Atea Study Site

Shimla, Himachal Pradesh, India

Atea Study Site

Belagavi, Karnataka, India

Atea Study Site

Kochi, Kerala, India

Atea Study Site

Mumbai, Maharashtra, India

Atea Study Site

Mumbai, Maharashtra, India

Atea Study Site

Nagpur, Maharashtra, India

Atea Study Site

Pune, Maharashtra, India

Atea Study Site

Pune, Maharashtra, India

Atea Study Site

Chandigarh, Punjab, India

Atea Study Site

Ludhiana, Punjab, India

Atea Study Site

Agra, Uttar Pradesh, India

Atea Study Site

Kanpur, Uttar Pradesh, India

Atea Study Site

Lucknow, Uttar Pradesh, India

Atea Study Site

Varanasi, Uttar Pradesh, India

Atea Study Site

Kolkata, West Bengal, India

Atea Study Site

Kota Bharu, Kelantan, Malaysia

Atea Study Site

Kota Bharu, Kelantan, Malaysia

Atea Study Site

Ampang, Kuala Lumpur, Malaysia

Atea Study Site

Kuantan, Pahang, Malaysia

Atea Study Site

Kota Kinabalu, Sabah, Malaysia

Atea Study Site

Kuala Lumpur, Malaysia

Atea Clinical Study Site

Chisinau, Moldova

Atea Study Site

Islamabad, Pakistan

Atea Study Site

Islamabad, Pakistan

Atea Study Site

Karachi, Pakistan

Atea Study Site

Karachi, Pakistan

Atea Study Site

Karachi, Pakistan

Atea Study Site

Karachi, Pakistan

Atea Study Site

Lahore, Pakistan

Atea Study Site

Lahore, Pakistan

Atea Study Site

Lahore, Pakistan

Atea Study Site

Peshawar, Pakistan

Atea Study Site

Rawalpindi, Pakistan

Atea Study Site

Krakow, Poland

Atea Study Site

Kłodzko, Poland

Atea Study Site

Lublin, Poland

Atea Study Site

Mysłowice, Poland

Atea Study Site

Warsaw, Poland

Atea Study Site

Wroclaw, Poland

Atea Study Site

Bucharest, Romania

Atea Study Site

Bucharest, Romania

Atea Study Site

Bucharest, Romania

Atea Study Site

Bucharest, Romania

Atea Study Site

Constanța, Romania

Atea Study Site

Craiova, Romania

Atea Study Site

Galati, Romania

Atea Study Site

Iași, Romania

Atea Study Site

Sibiu, Romania

Atea Study Site

Suceava, Romania

Atea Study Site

Port Elizabeth, Eastern Cape, South Africa

Atea Study Site

Bloemfontein, Free State, South Africa

Atea Study Site

Johannesburg, Gauteng, South Africa

Atea Study Site

Johannesburg, Gauteng, South Africa

Atea Study Site

Johannesburg, Gauteng, South Africa

Atea Study Site

Pretoria, Gauteng, South Africa

Atea Study Site

Brits, North West, South Africa

Atea Study Site

Somerset West, Western Cape, South Africa

Atea Study Site

Seoul, Gyeonggi-do, South Korea

Atea Study Site

Yangsan, Gyeongsangnam-do, South Korea

Atea Study Site

Busan, South Korea

Atea Study Site

Busan, South Korea

Atea Study Site

Seoul, South Korea

Atea Study Site

Santander, Cantabria, Spain

Atea Study Site

Málaga, Malaga, Spain

Atea Study Site

Vigo, Pontevedra, Spain

Atea Study Site

Barcelona, Spain

Atea Study Site

Pathum Wan, Bangkok, Thailand

Atea Study Site

Ratchathewi, Bangkok, Thailand

Atea Study Site

Mueang Nonthaburi, Changwat Khon Kaen, Thailand

Atea Study Site

Hat Yai, Changwat Songkhla, Thailand

Atea Study Site

Mueang Nonthaburi, Chiang Mai, Thailand

Atea Study Site

Bangkok, Thailand

Atea Study Site

Adana, Turkey (Türkiye)

Atea Study Site

Ankara, Turkey (Türkiye)

Atea Study Site

Ankara, Turkey (Türkiye)

Atea Study Site

Bursa, Turkey (Türkiye)

Atea Study Site

Denizli, Turkey (Türkiye)

Atea Study Site

Diyarbakır, Turkey (Türkiye)

Atea Study Site

Istanbul, Turkey (Türkiye)

Atea Study Site

Kayseri, Turkey (Türkiye)

Atea Study Site

Samsun, Turkey (Türkiye)

Atea Study Site

Kyiv, Ukraine

Atea Study Site

Lviv, Ukraine

Atea Study Site

Haiphong, Vietnam

Atea Study Site

Hanoi, Vietnam

Atea Study Site

Ho Chi Minh City, Vietnam

Atea Study Site

Ho Chi Minh City, Vietnam

Atea Study Site

Ho Chi Minh City, Vietnam

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07037277

Related Trials

Evaluation of Patients With Liver Disease

NCT000019711 location

Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

NCT0704031910 locations

The Australian HCV Point-of-Care Testing Program

NCT0504254469 locations

Evaluation of the Hepatoprotective Effects of a Nutritional Supplement in Patients With Liver Disease Secondary to Chronic Hepatitis C Virus Infection (RESQUETI Study).

NCT074876232 locations

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT012808251 location